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Text of summary  
Many genetic mutations implicated in Autism Spectrum Disorder (ASD) are in regulators of mRNA expression, 
processing, and translation. Among these, copy number variants of the UP-frameshift 2 (UPF2) gene that 
regulates nonsense-mediated mRNA decay (NMD) have been identified in patients with ASD. NMD is 
responsible for degrading mRNAs with a premature stop codon, an essential quality control mechanism limiting 
the creation of non-functional proteins. In Johnson et al., researchers identified new UPF2 variants in patients 
with language disorder and intellectual disability, and investigated the impact of Upf2 mutation in mouse and fly 
models. The results show that mice with Upf2 deletion in excitatory forebrain neurons exhibit impairments in 
learning that are recapitulated in the Upf2-deficient fly model. Upf2 deficient mice also showed a reduction in 
social interaction, as well as differences in ultrasonic vocalizations (USVs) indicative of altered communication. 
A transcriptomic analysis of the brains of Upf2-deficient mice revealed a surprising increase in genetic markers 
of inflammation, which was ultimately attributed to an increased number of immune cells in the brain along with 
elevated cytokine levels.. When the authors tested whether immunosuppressive drugs could reverse impairments 
in the Upf2 deficient mice, they found that treatment with either cyclophosphamide or minocycline could correct 
deficits in learning, social communication, and USVs. Collectively, these results indicate that disruption of 
neuronal Upf2 in mice heightens immune responses in the brain, causing behavioral changes reminiscent of ASD. 
 
This study provides further understanding of how genetic mutations impacting mRNA and protein processing 
could lead to the behavioral changes associated with ASD. In the case of UPF2 mutations, the pathological driver 
may be an increased activation of the brain immune system that can be targeted by immunosuppressive drugs. 
Now researchers can investigate whether mutations in other NMD regulators result in similar neurological 
impairments, and whether an immunosuppressive strategy is effective in treating patients with these mutations. A 
limitation of the study is the neuron-specific deletion of Upf2 in the mouse model, which does not directly match 
the global expression of  UPF2 variants in patients. Nevertheless, this study exemplifies the importance of 
investigating expression regulators such as Upf2 to determine how behavioral phenotypes arise, and to identify 
molecular changes that can be corrected by therapeutic intervention.  
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